





Malignant nails tumors

Christian Dumontier

Philippe Abimelec

Institut de la Main & Hôpital St Antoine, Paris

Malignant nail tumors

- Squamous cell carcinoma
 (Epidermoid carcinoma)
- Melanoma

- Metastasis
- ✓ Various bone sarcomas
- Kaposi sarcoma
- Basal cell carcinoma
- Lymphomas
- Merckel cell tumor
- Periungueal eccrine porocarcinoma
- Others

Take home message

- Malignant nail tumors are rare
- Even if diagnosis is suspected, tumors are only diagnosed by an experienced pathologist
- Squamous cell carcinoma is a malignant tumor due to a viral infection
- Melanoma is the most severe cancer but can be cured if diagnosed early

Squamous cell carcinoma

- Bowen's disease is a Squamous cell carcinoma (SCC) in situ
- Without treatment, 3-5% will evolve to SCC





Etiologies of Squamous cell carcinoma

- Emerging evidence that Bowen's disease is linked to oncogenic subtypes of HPV (HPV16-34,35 responsible for genital tract neoplasms)
- Immunosupression (transplant recipient, AIDS...) is a high risk factor for HPV induced tumors
- Exposure to Xrays, arsenic, trauma and chronic skin diseases have been associated to digital SCC in the past

Epidemiology

- Long delay in diagnosis (5-7 years)
- Third to sixth decade (# warts)
- Immunosupression (transplant recipient, AIDS ...)
- Fingers (thumbs especially) are more commonly affected than the toes
- Monodactylous or polydactylous lesions (Bowen's disease)





- Scalling and onycholysis that are disproportional to the verrucous changes,
- Periungueal pigmented scalling
- Lateral onycholysis with erosion of the nail bed



AIDS Patient

- Longitudinal melanonychia
- Periungueal swelling
- Acropachy
- Hyperkeratotic tumors and plaques
- Crusts
- Nail plate dystrophy
- Paronychia





• First, Think of it

- Biopsy of the lesion at different levels
 - Biopsies should be performed at the deepest portions of the lesion (ulceration, tumors) because
 - Some lesions may show intra-epidermal carcinoma in certain zone and invasive carcinoma in others

- Pathology requires an experimented dermatopathologist
 - Acanthosis with marked hyperkeratosis.
 - Anaplasia and disarray that involves its entire thickness.
 - Many epidermal cells are atypicals, dyskeratotic, multinucleated, pycnotic, necrotic or with large hyperchromatic nuclei, mitoses

- "Bowen's disease" is an intra-epidermal tumor that may evolve to an invasive squamous cell carcinoma
- It is extremely difficult to differentiate intraepidermal SCC from invasive SCC or from viral warts
- Multiple biopsies followed by a complete excision are often necessary



Wart



Bowen's disease



Invasive SCC



What to do?

• X ray to rule out bone invasion





Lymph node
 evaluation
 (epitrochleal, axillary)





What to do?

(with the help of a dermatologist)

- Complete cutaneous and digital examination to search for a polydactylous process (rare)
- Investigation of the patient's immune status
- Genital examination of the patient and his or her partner

Treatment of Squamous Cell Carcinoma


- Treatment of squamous cell carcinoma disease should be surgical and conservative and rely on a accurate diagnosis:
- intra-epidermal VS invasive SCC

Treatment of SCC

- Intra-epidermal squamous cell carcinoma ("Bowen's disease")
 - Early SCC may benefit from carbon dioxide laser vaporization
 - Total excision of the lesion with 3 mm margins is considered adequate (pathological control of the margins is mandatory)
 - Bleomycin intralesional injections, topical imiquimod or photodynamic therapy are under investigations

Bleomycin injection (experimental data)

• Immunosuppressed patient (heart transplant)




Surgical Treatment



Complete excision of the lesions





Treatment of invasive Squamous Cell Carcinoma

- Moh's micrographic surgery is the treatment of choice
- Total excision of the lesion with 5 mm margins is considered adequate (pathological control of the margins is mandatory)
- SCC invasive to the bone require amputation of the distal phalanx
- Axillary lymph node dissection should be performed in the presence of a palpable node, sentinel node biopsy should be considered otherwise

Treatment

• SCC invasive to the bone require amputation of the distal phalanx




After surgery, patients should undergo follow-ups at regular intervals

Evolution of the disease

- Prognosis of SCC is encouraging despite the frequent delay in diagnosis
- Evolution is mostly local with a very low risk of distant metastasis (lymph nodes)








Melanomas and longitudinal melanonychia

Melanomas

- Malignant neoplasm derived from melanocytes
- Represent 2-3 % of all melanomas in caucasians (rare lesions)
- Represent around 20% in individuals of dark skin races

Epidemiology

- Sixth decade
- Women > men




 Amelanotic melanoma account for 15-25% of nail melanomas



Problem in practice

- Low frequency of melanomas
 - 2/3 of Longitudinal melanonychia (LM) are secondary to melanocytic hyperactivity
 - 1/3 are naevi or lentigos
 - Only 5% are melanomas

Problem: Clinical diagnosis is very difficult even for experienced dermatologists



The difficulty in practice

- Melanomas seen early carry a very good prognosis
- But the diagnosis may be difficult or impossible on a partial biopsy
 - When the clinical picture is suggestive of a melanoma the biopsy SHOULD PREFERABLY INCLUDE ALL the lesion

- It means that
- Any excisional-biopsy of LM carries a high risk of permanent nail dystrophy




Histologic subtypes

- Acral lentiginous malignant melanoma
- Superficial spreading malignant melanoma
- Nodular malignant melanoma.

Less useful for nail melanomas

Prognosis

- Breslow's tumor thickness
 - < 0,75 mm
 - 0,75-1,5 mm
 - 1,5-4 mm
 - > 4mm



Prognosis

- Clark's level of invasion
 - I in situ
 - II invades the papillary dermis
 - III invades the papillary reticular-dermal interface
 - IV invades the reticular dermis
 - V invades the subcutaneous tissue

Prognosis

• Diagnostic delay! It is most often the fault of the doctor...





Diagnostic (early)

- Large, progressive LM (≥ 5 mm),
- Pigmentation of the periungueal tissue (Hutchinson sign) is frequent but not pathognomonic






Two years natural evolution of nail melanoma in a 34 years old lady who refused treatment

Breslow 0,66 mm / Clark Level II

Diagnostic (early)


- Progressive widening
 - (A proximal width of the band superior to the distal indicates a rapid growth rate)
- Thumb, index, great toe
- Traumatism



Breslow 0,55 / Clark level II

Diagnosis (early)

• Light brown bands but more often dark, with variegated colors and multiple fine linear streaks of denser hyperpigmentation.



Amelanotic melanoma 15-25 % of nail melanomas!





† , 54 yrs

Breslow 2,4 mm /Clark Level IV

Amelanotic melanoma 15-25 % of nail melanomas!





† , 33 yrs

Breslow 2,7 mm / Clark Level IV

♠ 62 yrs old, MDBreslow 0,45 mm7 yrs evolution

• Destruction of the nail plate or fissure

Diagnostic (too late...)

- Tumor
- Granulation tissue pigmented or not
- Ulceration of the nail bed associated with onycholysis or destruction of the nail plate
- Infection, bleeding or pain



Treatment

- Early diagnosis and surgical removal of NM is mandatory to improve currently poor survival rates.
- Surgical principles are similar to MM at other skin sites.
- Wide local surgical excision

Treatment

- Treatment guidelines of MM at other skin sites are well defined and rely upon Breslow thickness
- Recommended Surgical Margins for Melanoma*
 - T1 (<1.0 mm) 1 cm (radial)
 - T2 (1.1-2.0 mm) 1-2 cm, depending on location
 - T3 (2.1-4.0 mm) 2 cm
 - T4 (>4.0 mm) 3 cm
- (*Primary surgical closure whenever possible)

Treatment, 1st step

- A well-done biopsy
- Given in one piece, with orientation, to an experienced pathologist
- If negative, nail dystrophy should be limited

Lateral biopsies



• Margin 0,5 to 1 mm

Lateral biopsies



- Margin 0,5 to 1 mm
- Take off the lateral wall

- Margin 0,5 to 1 mm
- Take off the lateral wall
- Remove the ventral and proximal part of the matrix





Lateral biopsies

• Reconstruct the lateral wall using Dubois's flap





Central LIM < 1-2 mm


• Remove proximal part of the nail plate






Central LM < 1-2 mm

- Transverse excision
 - Closure with some tension








- Longitudinal excision
 - Close with Johnson's flap





Central LM > 3 mm

• Excision will be large (3 mm + 1 mm on each side) and nail dystrophy cannot be avoided



Central LM > 3 mm

- Closure with 1 (2) Schernberg's flap
- Leave it open (spontaneous healing) until the pathologist give the answer




Treatment (in situ melanoma)

- For malignant melanoma in situ we recommend complete excision of the nail apparatus to the underlying bone followed by a full thickness graft.
- No amputation (skin disease, not bone)









Our series

- 13 patients
- 9 Melanoma in situ
- 4 epidermoid carcinoma (2 Bowen's)



Our series

- 4 years FU
- No nail regrowth
- 5 mm Weber Twopoint discrimination
- Normal DIP mobility



No recurrence

Our series

- 5 epidermal cysts
- 2 patients had some difficulties to accept their fingers



Literature

- « old » literature favors amputation through the MP joint
- Recent papers (decade) favor amputation through the DIP/IP joint
- Most « recent » papers favor nail apparatus excision with nail reconstruction using nail skin graft

Treatment (late stages)

- Amputation
 - DIP/IP joint amputation is enough
 - No benefit of proximal over distal amputations
 - Level of amputation is chosen in order to obtain the best functional outcome

Other treatment

- Sentinel node biopsy
- Interferon
- Other protocols
 - For melanomas research projects
 - I have no experience

Take home message

- Malignant nail tumors are rare
- Nail dermatologist is needed to eliminate differential diagnosis which are not tumors
- Most tumors are only diagnosed by an experienced pathologist
- Any surgeon must have a high suspicion of melanoma facing a patient with a melanonychia